José Dinis

José Dinis

Auto-generated profile, based on publicly available information

José Dinis

Department of Medical Oncology. Instituto Português de Oncologia do Porto. Porto. & Clinical Research Unit. Research Center of Instituto Português de Oncologia do Porto. Porto

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Lancet
Verified
Journal Article
Closed access
ECEzra E W Cohen
Ezra E W Cohen
CTChristophe Le Tourneau
Christophe Le Tourneau
LLLisa Licitra
Lisa Licitra
MAMyung-Ju Ahn
Myung-Ju Ahn
ASAinara Soria
Ainara Soria
DZDan Zandberg
Dan Zandberg

10 April 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SGSteven Grunberg
Steven Grunberg
DCDaniel Chua
Daniel Chua
AMAnish Maru
Anish Maru
JDJosé Dinis
José Dinis
SDSuzanne DeVandry
Suzanne DeVandry
JHJørn Herrstedt
Jørn Herrstedt
Purpose: Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours). Therefore, recommended antiemetic regimens include multiple-day NK1RA administration. Preliminary data suggested that single-dose aprepitant before chemotherapy could provide CINV protection throughout the overall risk phase (OP; 0 to 120 hours). This study compared a 3-day oral aprepitant schedule to a regimen containing a single dose of the intravenous NK1RA fosaprepitant. Patients and Methods: A randomized, double-blind, active-control design was used to test whether fosaprepitant is noninferior to aprepitant. Patients receiving cisplatin ≥ 70 mg/m2 for the first time received ondansetron and dexamethasone with a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3) or a single-dose fosaprepitant regimen (150 mg on day 1). The primary end point was complete response (CR; no vomiting, no rescue medication) during OP. Secondary end points were CR during DP and no vomiting during OP. Accrual of 1,113 evaluable patients per treatment arm was planned to confirm noninferiority with expected CR of 67.7% and noninferiority margin of minus 7 percentage points. Results: A total of 2,322 patients were randomly assigned, and 2,247 were evaluable for efficacy. Antiemetic protection with aprepitant and fosaprepitant was equivalent within predefined bounds for noninferiority. Both regimens were well tolerated, although more frequent infusion site pain/erythema/thrombophlebitis was seen with fosaprepitant relative to aprepitant (2.7% v 0.3%, respectively). Conclusion: Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.

9 April 2014 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
VSVassiliki Saloura
Vassiliki Saloura
ECEzra E. W. Cohen
Ezra E. W. Cohen
LLLisa Licitra
Lisa Licitra
SBSalem Billan
Salem Billan
JDJose Dinis
Jose Dinis
TGThomas C. Gauler
Thomas C. Gauler

18 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ECE.E. Cohen
E.E. Cohen
KHKevin Harrington
Kevin Harrington
CTC. Le Tourneau
C. Le Tourneau
JDJ. Dinis
J. Dinis
LLL. Licitra
L. Licitra
DSD. Soulieres
D. Soulieres
Background: Pembro showed antitumor activity and manageable toxicity in R/M HNSCC in an extended phase 1b study. KEYNOTE-040 (NCT02252042) was a global, open-label, phase 3 study of pembro vs SOC for R/M HNSCC.

29 April 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JFJérôme Fayette
Jérôme Fayette
LLLisa Licitra
Lisa Licitra
KHKevin Harrington
Kevin Harrington
RHRobert Haddad
Robert Haddad
LSLillian L. Siu
Lillian L. Siu
DADouglas R. Adkins
Douglas R. Adkins
Purpose: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that monalizumab plus cetuximab had clinical activity in R/M HNSCC. Patients and Methods: INTERLINK-1 (NCT04590963) was a double-blind, phase III study. Participants with R/M HNSCC who had received immune checkpoint inhibitor therapy and progressed despite platinum-based chemotherapy were randomized 2:1 to monalizumab (750 mg, every 2 weeks) or placebo, plus cetuximab (400 mg/m2 loading dose, then 250 mg/m2, weekly). The primary endpoint was overall survival (OS) in participants with non-oropharyngeal cancer or human papillomavirus (HPV)-negative oropharyngeal cancer (HPV-unrelated analysis set). Secondary endpoints included progression-free survival and objective response rate. Results: At data cutoff, 216 participants were randomized in the HPV-unrelated analysis set: 145 to monalizumab plus cetuximab and 71 to placebo plus cetuximab. Median OS was 8.8 months for monalizumab plus cetuximab versus 8.6 months for placebo plus cetuximab (HR, 1.00; 95% confidence interval, 0.66–1.54); median progression-free survival was 3.6 versus 3.8 months, respectively (HR, 1.11; 95% confidence interval, 0.79–1.57); and the objective response rate was 15.2% versus 23.9%, respectively. INTERLINK-1 was terminated after a preplanned interim analysis showed that futility criteria were met (predetermined futility HR >0.874). Grade 3/4 treatment–related adverse events were reported in 18.3% and 17.2% of participants treated in the monalizumab and placebo arms, respectively. Conclusions: Monalizumab plus cetuximab did not improve OS compared with placebo plus cetuximab. The safety profile of the combination was consistent with safety observations for cetuximab monotherapy.

14 May 2010 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MSMara Silva
Mara Silva
IVIsabel Veiga
Isabel Veiga
FRFranclim R Ribeiro
Franclim R Ribeiro
JVJoana Vieira
Joana Vieira
CPCarla Pinto
Carla Pinto
MTManuel R. Teixeira
Manuel R. Teixeira
Oncogenic point mutations in KIT or PDGFRA are recognized as the primary events responsible for the pathogenesis of most gastrointestinal stromal tumors (GIST), but additional genomic alterations are frequent and presumably required for tumor progression. The relative contribution of such alterations for the biology and clinical behavior of GIST, however, remains elusive.